Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity

Item Type:Article
Title:PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity
Creators Name:Kim, H. and Kim, H. and Feng, Y. and Li, Y. and Tamiya, H. and Tocci, S. and Ronai, Z.A.
Abstract:Protein arginine methyltransferase 5 (PRMT5) controls diverse cellular processes and is implicated in cancer development and progression. Here, we report an inverse correlation between PRMT5 function and antitumor immunity. PRMT5 expression was associated with an antitumor immune gene signature in human melanoma tissue. Reducing PRMT5 activity antagonized melanoma growth in immunocompetent but not immunocompromised mice. PRMT5 methylation of IFI16 [interferon-γ (IFN-γ)-inducible protein 16] or its murine homolog IFI204, which are components of the cGAS/STING (stimulator of IFN genes) pathway, attenuated cytosolic DNA-induced IFN and chemokine expression in melanoma cells. PRMT5 also inhibited transcription of the gene encoding NLRC5 (nucleotide-binding oligomerization domain-like receptor family caspase recruitment domain containing 5), a protein that promotes the expression of genes implicated in major histocompatibility complex class I (MHCI) antigen presentation. PRMT5 knockdown augmented IFN and chemokine production and increased MHCI abundance in melanoma. Increased expression of IFI204 and NLRC5 was associated with decreased melanoma growth in murine models, and increased expression of IFI16 and NLRC5 correlated with prolonged survival of patients with melanoma. Combination of pharmacological (GSK3326595) or genetic (shRNA) inhibition of PRMT5 with immune checkpoint therapy limited growth of murine melanoma tumors (B16F10 and YUMM1.7) and enhanced therapeutic efficacy, compared with the effect of either treatment alone. Overall, our findings provide a rationale to test PRMT5 inhibitors in immunotherapy-based clinical trials as a means to enhance an antitumor immune response.
Keywords:Gene Expression, Intracellular Signaling Peptides and Proteins, Melanoma, Methylation, Nucleotidyltransferases, Small Interfering RNA, Animals, Mice
Source:Science Translational Medicine
ISSN:1946-6234
Publisher:American Association for the Advancement of Science
Volume:12
Number:551
Page Range:eaaz5683
Date:8 July 2020
Additional Information:Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
Official Publication:https://doi.org/10.1126/scitranslmed.aaz5683
External Fulltext:View full text on PubMed Central
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library